D-Trp6-luteinizing hormone-releasing hormone inhibits sulpiride-induced hyperprolactinemia in normal men

M. A. Rubio, I. Torres-Aleman, J. R. Calle, J. A. Cabranes, Andrew V Schally, A. L. Charro

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The effect of a potent agonistic analog of LHRH, D-Trp6-LHRH, on hyperprolactinemia induced by sulpiride was studied in normal men. Six men received sulpiride (100 mg, twice daily, orally) for 44 days. D-Trp6-LHRH was given sc during the last 2 weeks of sulpiride administration; the dose was 500 ng on the first day and 100 μg daily for the subsequent 14 days. All men had high serum PRL levels before D-Trp6-LHRH administration (mean ± SEM, 56 ± 9 ng/mL), which decreased significantly after the first dose of the analog (45 ± 5 ng/mL; P = 0.031) and also after 15 days of analog administration (41 ± 6 ng/mL; P = 0.016). These data demonstrate that administration of LHRH agonist can inhibit the hyperprolactinemic effect of sulpiride, suggesting a direct action of the analog on the pituitary gland to modulate PRL secretion.

Original languageEnglish (US)
Pages (from-to)368-369
Number of pages2
JournalJournal of Clinical Endocrinology and Metabolism
Volume65
Issue number2
DOIs
StatePublished - 1987
Externally publishedYes

Fingerprint

Sulpiride
Hyperprolactinemia
Gonadotropin-Releasing Hormone
Pituitary Gland
Scanning electron microscopy
Serum

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

D-Trp6-luteinizing hormone-releasing hormone inhibits sulpiride-induced hyperprolactinemia in normal men. / Rubio, M. A.; Torres-Aleman, I.; Calle, J. R.; Cabranes, J. A.; Schally, Andrew V; Charro, A. L.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 65, No. 2, 1987, p. 368-369.

Research output: Contribution to journalArticle

Rubio, M. A. ; Torres-Aleman, I. ; Calle, J. R. ; Cabranes, J. A. ; Schally, Andrew V ; Charro, A. L. / D-Trp6-luteinizing hormone-releasing hormone inhibits sulpiride-induced hyperprolactinemia in normal men. In: Journal of Clinical Endocrinology and Metabolism. 1987 ; Vol. 65, No. 2. pp. 368-369.
@article{d465214cdc7447cfa0fcc96859929f6e,
title = "D-Trp6-luteinizing hormone-releasing hormone inhibits sulpiride-induced hyperprolactinemia in normal men",
abstract = "The effect of a potent agonistic analog of LHRH, D-Trp6-LHRH, on hyperprolactinemia induced by sulpiride was studied in normal men. Six men received sulpiride (100 mg, twice daily, orally) for 44 days. D-Trp6-LHRH was given sc during the last 2 weeks of sulpiride administration; the dose was 500 ng on the first day and 100 μg daily for the subsequent 14 days. All men had high serum PRL levels before D-Trp6-LHRH administration (mean ± SEM, 56 ± 9 ng/mL), which decreased significantly after the first dose of the analog (45 ± 5 ng/mL; P = 0.031) and also after 15 days of analog administration (41 ± 6 ng/mL; P = 0.016). These data demonstrate that administration of LHRH agonist can inhibit the hyperprolactinemic effect of sulpiride, suggesting a direct action of the analog on the pituitary gland to modulate PRL secretion.",
author = "Rubio, {M. A.} and I. Torres-Aleman and Calle, {J. R.} and Cabranes, {J. A.} and Schally, {Andrew V} and Charro, {A. L.}",
year = "1987",
doi = "10.1210/jcem-65-2-368",
language = "English (US)",
volume = "65",
pages = "368--369",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - D-Trp6-luteinizing hormone-releasing hormone inhibits sulpiride-induced hyperprolactinemia in normal men

AU - Rubio, M. A.

AU - Torres-Aleman, I.

AU - Calle, J. R.

AU - Cabranes, J. A.

AU - Schally, Andrew V

AU - Charro, A. L.

PY - 1987

Y1 - 1987

N2 - The effect of a potent agonistic analog of LHRH, D-Trp6-LHRH, on hyperprolactinemia induced by sulpiride was studied in normal men. Six men received sulpiride (100 mg, twice daily, orally) for 44 days. D-Trp6-LHRH was given sc during the last 2 weeks of sulpiride administration; the dose was 500 ng on the first day and 100 μg daily for the subsequent 14 days. All men had high serum PRL levels before D-Trp6-LHRH administration (mean ± SEM, 56 ± 9 ng/mL), which decreased significantly after the first dose of the analog (45 ± 5 ng/mL; P = 0.031) and also after 15 days of analog administration (41 ± 6 ng/mL; P = 0.016). These data demonstrate that administration of LHRH agonist can inhibit the hyperprolactinemic effect of sulpiride, suggesting a direct action of the analog on the pituitary gland to modulate PRL secretion.

AB - The effect of a potent agonistic analog of LHRH, D-Trp6-LHRH, on hyperprolactinemia induced by sulpiride was studied in normal men. Six men received sulpiride (100 mg, twice daily, orally) for 44 days. D-Trp6-LHRH was given sc during the last 2 weeks of sulpiride administration; the dose was 500 ng on the first day and 100 μg daily for the subsequent 14 days. All men had high serum PRL levels before D-Trp6-LHRH administration (mean ± SEM, 56 ± 9 ng/mL), which decreased significantly after the first dose of the analog (45 ± 5 ng/mL; P = 0.031) and also after 15 days of analog administration (41 ± 6 ng/mL; P = 0.016). These data demonstrate that administration of LHRH agonist can inhibit the hyperprolactinemic effect of sulpiride, suggesting a direct action of the analog on the pituitary gland to modulate PRL secretion.

UR - http://www.scopus.com/inward/record.url?scp=0023161624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023161624&partnerID=8YFLogxK

U2 - 10.1210/jcem-65-2-368

DO - 10.1210/jcem-65-2-368

M3 - Article

VL - 65

SP - 368

EP - 369

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 2

ER -